Stay updated on Bispecific Antibody MCLA-158 Clinical Trial
Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page footer now identifies the site as revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the Phase 1/2 MCLA-158 study is displayed with its recruitment information, participating locations, eligibility criteria, treatment arms, and outcome measures.SummaryDifference100%

- Check15 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0; the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH notice was added announcing a transition from “Artificial Intelligence” to “Super Intelligence,” and the footer revision advanced from v3.7.1 to v3.7.2. The page still displays a 403 Forbidden error.SummaryDifference1%

- Check43 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the usual content with an error message; the additions include a 403 header and a Home link, and the detailed study information is no longer accessible.SummaryDifference21%

Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.